Dr. Reddy’s Laboratories Ltd. reported a 14% year-on-year rise in net profit to Rs. 1,437 crore for the quarter ended September 2025, driven by robust sales in the U.S. generics market and steady growth in India. The pharmaceutical major benefited from a strong product mix, operational efficiency, and cost discipline, which offset pricing pressures in select markets. Revenue grew steadily across key geographies, while new product launches and a healthy pipeline strengthened its competitive position. With consistent performance and strategic focus on innovation, Dr.